Laura Hindley's questions to Novo Nordisk A/S (NVO) leadership • Q1 2024
Question
Laura Hindley asked about the potential to apply once-monthly technology to other pipeline assets like amycretin or CagriSema and whether this technology influenced the development of the once-weekly GLP-1/GIP.
Answer
Martin Lange, Head of R&D, explained that the company is exploring several modalities for extended drug action. While the current once-monthly technology could potentially be applied elsewhere, the final decision for any asset will depend on a balance of efficacy and manufacturing scalability. The current trial is an initial exploration of the technology's potential.